Last week, the FDA gave breakthrough status to a drug, Lynparza (olaparib, AstraZeneca), for treating some forms of metastatic prostate cancer. This means the agency will expedite review and possible approval of this new kind of therapy, a PARP inhibitor for men with advanced, refractory prostate cancer. Read more